You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

Citation Tools

Article menu
Immune cell therapies and immune cell engineering
Original research
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Nalawade SA, Shafer P, Bajgain P, et al
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
Journal for ImmunoTherapy of Cancer 2021;9:e003237. doi: 10.1136/jitc-2021-003237